Company Overview - Adaptive Biotechnologies utilizes a proprietary immune medicine platform focused on disease diagnosis and monitoring, particularly in oncology and immune-related conditions [6] - The company has strategic partnerships with Genentech and Microsoft, enhancing its commercialization capabilities [6][8] - As of March 27, 2026, the company's market capitalization is $1.91 billion, with a revenue of $276.98 million and a 1-year price change of 51% [5] Transaction Summary - Julie Rubinstein, President and COO, sold 81,342 shares for approximately $1.21 million, reflecting a transaction value based on a weighted average purchase price of $14.90 [1][2] - Post-transaction, Rubinstein holds 643,471 shares, valued at around $9.34 million based on the market close of $14.52 [2] - The sale represents an 11.22% reduction in her direct common stock holdings [6][9] Market Context - The transactions occurred when Adaptive Biotechnologies shares were priced around $14.90, with a stock return of about 118% over the prior year, indicating a favorable environment for executive liquidity events [4] - Despite a recent cooling in share prices, the stock remains up over 50% year-over-year [4] Business Performance - The core product, clonoSEQ, detects residual cancer cells in blood cancers, contributing to a 46% revenue growth in 2025 and achieving profitability [10] - The company is guiding for positive adjusted EBITDA and free cash flow by year-end 2026, marking a significant turnaround from a loss of $80 million on an adjusted basis two years prior [10]

Core Insights - The recent insider sales by Francis Lo, Chief People Officer at Adaptive Biotechnologies, totaling nearly $1 million, were primarily routine transactions rather than indicative of a loss of confidence in the company's stock [1][4][5] Company Performance - Adaptive Biotechnologies has shown strong performance, with shares delivering a 105% total return over the past year leading up to the sales [2][6] - The company reported a 55% year-over-year revenue growth in its latest earnings report, with the minimal residual disease (MRD) segment, driven by its flagship test clonoSEQ, achieving a 46% revenue growth and turning positive on Adjusted EBITDA in Q4 [6] Insider Holdings - After the sales, Lo retains a significant stake in the company, holding 291,374 shares directly and 2,500 shares indirectly, valued at approximately $4.1 million based on current prices [3][7] Market Context - The sales were executed under different frameworks: one was a mandated "sell to cover" for tax obligations, while the other was part of a pre-scheduled trading plan [4][5] - The competitive landscape in the MRD space is intensifying, particularly with Natera's acquisition of Foresight Diagnostics, which introduces a well-funded competitor [6] Investment Considerations - For investors interested in the biotech diagnostics sector, Adaptive Biotechnologies' immune profiling platform is central to its investment case [8]

Core Insights - Adaptive Biotechnologies' stock experienced a 5.8% increase, closing at $13.17, following a significant trading volume, contrasting with a 19.9% decline over the past month [1] - The positive investor sentiment is driven by the potential of the company's pipeline, particularly its lead product clonoSEQ, which monitors minimal residual disease in hematologic cancers [2] - The company is advancing its Immune Medicine platform to discover T-cell receptor-based therapeutics for various diseases, alongside research programs aimed at identifying disease-specific immune responses [2] Financial Expectations - The company is projected to report a quarterly loss of $0.16 per share, reflecting a year-over-year increase of 20%, with expected revenues of $61.84 million, up 17.9% from the previous year [3] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Adaptive Biotechnologies holds a Zacks Rank of 3 (Hold) within the Medical - Biomedical and Genetics industry, which includes other companies like AnaptysBio, Inc. [5] - AnaptysBio's EPS estimate has seen a significant revision of +34.5% over the past month, indicating a change of +43.8% from the previous year, also holding a Zacks Rank of 3 (Hold) [6]

Summary of Adaptive Biotechnologies FY Conference Call Company Overview - **Company**: Adaptive Biotechnologies (NasdaqGS:ADPT) - **Industry**: Life Sciences, specifically focusing on diagnostics and immune medicine Key Points and Arguments 1. Strong Performance in 2025 - The company reported accelerated volume growth, multiple guideline inclusions, and improvements in average selling price (ASP) for its clinical business in 2025, setting a positive outlook for 2026 [4][3] 2. Growth Expectations for 2026 - The company anticipates greater than 30% ClonoSEQ volume growth for 2026, building on the successful strategies implemented in the previous year [5][8] - Five key growth drivers identified: blood-based testing, community presence, guideline inclusion, increased data generation, and EMR integration [5][4] 3. Community vs. Academic Testing - Testing distribution at the end of the previous year was 33% community and 67% academic, with expectations to reach 35% community by the end of 2026 [11][12] - Community testing is growing at approximately 14%, while academic testing is growing at about 8-9% [11][12] 4. EMR Integration and Repeat Testing - EMR integration has significantly improved the ease of ordering tests, with 75% of doctors utilizing repeat ordering functions [13][14] - Compliance rates for repeat testing are around 63-65% [14] 5. Guideline Inclusions and Their Impact - The company has achieved five guideline inclusions across various indications, with a typical lag of 6-9 months before these changes impact ordering patterns [17][18] 6. Clinical Trials and Potential Updates - Upcoming interim readouts from trials such as MASTER-2 and BOVen could lead to practice-changing updates in guidelines for multiple myeloma and CLL [19][24] 7. Pricing Strategy - The ASP increased from $1,117 to $1,307 (17% increase) last year, with a projected increase to $1,400 (7% increase) this year [36][37] - Factors contributing to price increases include new payer contracts and improved revenue cycle management [38][39] 8. Competitive Landscape - The company positions ClonoSEQ as the gold standard in hematological MRD testing, emphasizing its specificity and sensitivity compared to competitors like Natera [72][74] - The market for DLBCL is under-penetrated, with only 3% penetration, presenting an opportunity for growth [75] 9. International Expansion Plans - The company is pursuing a capital-efficient technology transfer model for international markets, with successful implementations in several countries [64][66] 10. Financial Outlook - The company aims for gross margins of 75-80% and operating margins of 20-25% as it scales operations [87][88] - The MRD business is expected to continue its growth trajectory, with significant potential in the immune medicine sector as well [91][92] Additional Important Insights - The company is focused on enhancing market access and reimbursement policies, particularly for recurrence monitoring and expanding test bundles [57][62] - The immune medicine business is viewed as a significant growth opportunity, with ongoing investments in data generation [91][92] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting Adaptive Biotechnologies' growth potential and competitive positioning in the life sciences industry.

Core Insights - Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is recognized as a promising stock under $20 following its fiscal Q4 and full-year 2025 earnings release on February 5 [1] Group 1: Earnings and Ratings Updates - TD Cowen raised the price target for ADPT to $21 from $20 while maintaining a Buy rating after the fiscal Q4 earnings beat, citing positive signals from various drivers such as the shift to blood-based tests and EMR integrations [2] - BTIG also increased the price target for ADPT to $22 from $21, keeping a Buy rating, and noted that the company is performing strongly in the specialty labs sector [3] - JPMorgan updated its rating for ADPT, raising the price target to $21 from $20 and maintaining an Overweight rating [3] Group 2: Company Overview - Adaptive Biotechnologies Corporation is focused on developing an immune medicine platform, offering services and products like immunoSEQ, clonoSEQ, cellular therapy, and vaccines [4]

Core Viewpoint - Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is experiencing positive momentum with multiple analysts upgrading their price targets following a strong Q4 earnings report, highlighting its growth potential in the specialty labs sector. Group 1: Analyst Upgrades - TD Cowen upgraded the price target for Adaptive Biotechnologies from $20 to $21 while maintaining a Buy rating, citing factors such as community adoption and a shift to blood-based testing as key drivers [1] - BTIG maintained a Buy rating and increased the price target from $21 to $22, describing the company as a leading growth story in specialty labs [2] - JPMorgan raised the price objective from $20 to $21 while retaining an Overweight rating, noting strong Q4 results and projecting FY26 MRD business revenue between $255 million and $265 million [3] Group 2: Company Overview - Adaptive Biotechnologies develops an immune medicine platform, offering products such as immunoSEQ, clonoSEQ, cellular treatment, and vaccinations [5]

Financial Data and Key Metrics Changes - Total company revenue for Q4 2025 was $71.7 million, representing a 63% year-over-year increase, while full-year revenue was $277 million, reflecting a 55% growth compared to the previous year [20][21] - Adjusted EBITDA for Q4 was $4.1 million, a significant improvement from a loss of $16.4 million in the same quarter last year, and for the full year, adjusted EBITDA was $12.2 million compared to a loss of $80.4 million in 2024 [21][22] - The net loss for Q4 was $13.6 million, and for the full year, it was $59.5 million [22] Business Line Data and Key Metrics Changes - In the MRD business, full-year revenue grew 46% year-over-year, with clinical testing revenue increasing 64% for the full year and 59% in Q4 [5][8] - clonoSEQ test volume reached 30,038 tests in Q4, up 43% year-over-year, with blood-based testing accounting for 47% of tests, an increase from 41% a year ago [8][9] - Immune medicine revenue was $9.8 million in Q4, up from $3.8 million a year ago, primarily driven by data licensing agreements with Pfizer [23] Market Data and Key Metrics Changes - The MRD pharma business saw a revenue growth of 20% year-over-year, with multiple myeloma accounting for roughly 70% of sequencing revenue [12] - The average ASP in the U.S. for clonoSEQ tests was $1,307, up 17% year-over-year, and the company expects to reach an average of $1,400 per test in 2026 [10][11] Company Strategy and Development Direction - The company aims to continue driving top-line growth while expanding margins, focusing on MRD revenue growth and profitability [14][27] - In immune medicine, the strategy includes advancing TCR antigen datasets and AI/ML modeling work, with a target net cash burn of $15-$20 million [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving strong sequential growth in Q1 2026 despite potential weather-related impacts on sample arrival [32] - The company anticipates clonoSEQ test volumes to grow by more than 30% year-over-year in 2026, supported by a shift towards blood-based testing and deeper community penetration [15][16] Other Important Information - The company ended the year with a strong cash balance of $227 million, excluding cash held by digital biotechnologies [24] - The MRD business is expected to generate between $255-$265 million in revenue for 2026, with a focus on maintaining disciplined spending and achieving positive adjusted EBITDA [25][26] Q&A Session Summary Question: Discussion on clonoSEQ volume trends and seasonality - Management noted that Q4 results indicate strong growth and that Q1 typically experiences some seasonality due to holidays and weather, but they remain confident in their guidance for the year [30][32] Question: Penetration rates in DLBCL and competition - Management highlighted that while DLBCL penetration is currently low, they are focusing on data generation, guideline advancements, and deepening pharma relationships to drive growth [34][36] Question: Competitor's flow cytometry assay and pricing - Management emphasized that their clonoSEQ assay is more sensitive than competitors' offerings, which positions them favorably in the market [41][43] Question: ASP pacing and payer negotiations - Management indicated that ASP growth is expected to be linear, with ongoing negotiations with key payers that could impact overall pricing [44][60] Question: EBITDA guidance for 2026 - Management clarified that they expect to achieve positive adjusted EBITDA by the end of Q4 2026, with MRD business already positive [48][49] Question: Community and blood-based testing growth assumptions - Management expressed confidence in the potential for further growth in both community and blood-based testing, with ongoing investments to drive these areas [50][52] Question: Monetization of immune medicine data - Management discussed the potential for additional data licensing deals and the value of their proprietary dataset in immunology applications [74][75]

Financial Data and Key Metrics Changes - Total company revenue for Q4 2025 was $71.7 million, representing a 63% year-over-year increase, while full-year revenue was $277 million, reflecting a 55% growth compared to the previous year [20][21] - Adjusted EBITDA for Q4 was $4.1 million, a significant improvement from a loss of $16.4 million in the same quarter last year, and for the full year, adjusted EBITDA was $12.2 million compared to a loss of $80.4 million in 2024 [21][22] - The net loss for Q4 was $13.6 million, and for the full year, it was $59.5 million [22] Business Line Data and Key Metrics Changes - In the MRD business, full-year revenue grew 46% year-over-year, with clinical testing revenue increasing 64% for the full year and 59% in Q4 [5][8] - clonoSEQ test volume reached 30,038 tests in Q4, up 43% year-over-year, with blood-based testing accounting for 47% of total tests [8][9] - Immune Medicine revenue was $9.8 million in Q4, up from $3.8 million a year ago, primarily driven by data licensing agreements with Pfizer [22][23] Market Data and Key Metrics Changes - The MRD pharma business saw a revenue growth of 20% year-over-year, with multiple myeloma accounting for roughly 70% of sequencing revenue [12] - The average ASP in the U.S. for clonoSEQ tests was $1,307, up 17% year-over-year, and the company expects to reach approximately $1,400 per test in 2026 [10][11] Company Strategy and Development Direction - The company aims to continue driving top-line growth while expanding margins, focusing on MRD revenue growth and profitability [14][27] - In 2026, the company expects clonoSEQ test volumes to grow by more than 30% year-over-year, with a significant shift towards blood-based testing [15][16] - The Immune Medicine business is focusing on generating large-scale proprietary immune receptor data and monetizing this data through partnerships [18][19] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving positive adjusted EBITDA and free cash flow by the end of 2026, with a focus on disciplined spending and operational efficiency [26] - The company is optimistic about the momentum in MRD and the potential for continued growth in the Immune Medicine sector [27] Other Important Information - The company ended the year with a strong cash position of $227 million, providing flexibility for future investments [22][24] - The company plans to maintain a disciplined capital allocation strategy, with a target net cash burn of $15 million to $20 million for the Immune Medicine business in 2026 [19] Q&A Session Summary Question: Discussion on clonoSEQ volume trends and seasonality - Management acknowledged Q4's strong results and noted that Q1 typically experiences some seasonality due to holidays and weather, but they remain confident in achieving strong sequential growth in Q1 [30][32] Question: Penetration rates in DLBCL and competition - Management highlighted the importance of data generation, guideline advancements, and deepening penetration with pharma to increase market share in DLBCL, where current penetration is low [34][36] Question: Competitive flow cytometry assay and pricing - Management emphasized that flow-based methods are inherently less sensitive than clonoSEQ, which maintains a significant advantage in sensitivity for myeloma testing [40][42] Question: ASP pacing and payer negotiations - Management indicated that ASP growth is expected to be linear, with ongoing negotiations with key payers that could impact ASP realization [43][44] Question: EBITDA guidance for 2026 - Management clarified that they expect to achieve positive adjusted EBITDA by the end of Q4 2026, with MRD expected to contribute positively [46][47] Question: Community and blood-based testing growth assumptions - Management expressed confidence in the potential for further growth in blood-based testing and community penetration, with ongoing investments to drive these areas [50][51] Question: Monetization of the Immune Medicine data - Management discussed the potential for additional data licensing deals and the value of their proprietary dataset in various immunology applications [72][73]

Financial Data and Key Metrics Changes - Total company revenue for Q4 2025 was $71.7 million, representing a 63% year-over-year increase, while full-year revenue was $277 million, reflecting a 55% growth compared to the previous year [19][20] - Adjusted EBITDA for Q4 was $4.1 million, a significant improvement from a loss of $16.4 million in the same quarter last year, and for the full year, adjusted EBITDA was $12.2 million compared to a loss of $80.4 million in 2024 [19][20] - The net loss for Q4 was $13.6 million, and for the full year, it was $59.5 million [20] Business Line Data and Key Metrics Changes - In the MRD business, revenue grew 54% year-over-year in Q4, with clinical and pharma contributions of 67% and 33%, respectively [20] - clonoSEQ test volume increased by 43% year-over-year, reaching 30,038 tests in Q4 [20] - Immune medicine revenue was $9.8 million in Q4, up from $3.8 million a year ago, primarily driven by data licensing agreements with Pfizer [21] Market Data and Key Metrics Changes - The MRD pharma business saw a revenue growth of 20% year-over-year, with multiple myeloma accounting for approximately 70% of sequencing revenue [11] - The average ASP in the U.S. for clonoSEQ tests was $1,307, up 17% year-over-year, and the company expects to increase it to approximately $1,400 per test in 2026 [10][24] Company Strategy and Development Direction - The company aims to continue driving top-line growth while expanding margins, focusing on MRD revenue growth and profitability [12][15] - In immune medicine, the strategy includes advancing TCR antigen datasets and AI/ML modeling work, with a target net cash burn of $15-$20 million [18] - The company plans to leverage its large-scale proprietary data for monetization through licensing deals, particularly in immunology applications [17][75] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving strong sequential growth in Q1 2026 despite potential weather-related impacts on sample arrival [31] - The company anticipates continued growth in clonoSEQ test volumes, with expectations of over 30% year-over-year growth supported by blood-based testing and deeper community penetration [13][14] - Management highlighted the importance of maintaining a strong cash position, ending 2025 with $227 million in cash, cash equivalents, and marketable securities [23] Other Important Information - The company achieved a 68% reduction in cash burn, indicating improved operational efficiency [6] - The MRD business is expected to generate between $255-$265 million in revenue for 2026, with a focus on expanding market presence and leveraging existing infrastructure [24] Q&A Session Summary Question: Can you discuss the sequential step up in clonoSEQ volume and any seasonality? - Management noted that Q4 results demonstrated strong growth and that Q1 typically experiences some seasonality due to holidays and weather, but they remain confident in achieving strong growth in Q1 [30][31] Question: How should we think about penetration rates in DLBCL? - Management indicated that they are applying lessons learned from multiple myeloma to increase penetration in DLBCL, focusing on data generation and expanding commercial payer coverage [32][34] Question: Thoughts on a competitor's flow cytometry assay? - Management emphasized that flow-based methods are inherently less sensitive than clonoSEQ, which maintains a significant advantage in sensitivity for MRD assessment [40][42] Question: Can you elaborate on the EBITDA guidance for 2026? - Management clarified that they expect to achieve positive adjusted EBITDA by the end of Q4 2026, with MRD already contributing positively [46][48] Question: What are the expectations for ASP growth in 2026? - Management indicated that ASP growth is expected to be linear, with ongoing negotiations with key payers influencing the final rates [58][60]

Fourth Quarter and FY 2025 Earnings Conference Call © Copyright Adaptive Biotechnologies 2026. Safe Harbor This presentation has been prepared by Adaptive Biotechnologies Corporation ("we," "us," "our," "Adaptive" or the "Company") and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all relevant information. Statements contained herein are made as of the date of this presentation unless stated otherwise. This presentation shall not cons ...